TYGACIL has proven clinical efficacy as monotherapy in complicated intra-abdominal infections (cIAI).1 In fact, empiric monotherapy with TYGACIL provided clinical cure rates comparable to imipenem/cilastatin in cIAI.1,27
Clinical cure rates (%) in cIAI in microbiologically evaluable patients (n/N)
* TYGACIL 100 mg initial dose, followed by 50 mg every 12 hours for 5 to 14 days.
† Imipenem/cilastatin 500/500 mg every 6 hours for 5 to 14 days.1
Data from two randomized, double-blind, active-controlled, multinational, multicenter studies of 1,642 patients.27
Cure = the course of TYGACIL and initial intervention (operative or radiographically controlled drainage procedure) resolved
the intra-abdominal infection.27
Cure rates by clinical diagnosis in cIAI at test of cure in microbiologically evaluable patients27
| Diagnosis | TYGACIL monotherapy % (n/N) |
Imipenem/cilastatin % (n/N) |
|---|---|---|
| Complicated appendicitis | 88.2% (232/263) | 89.3% (234/262) |
| Complicated cholecystitis | 97.1% (67/69) | 94.6% (70/74) |
| Perforation of the intestines | 74.5% (38/51) | 72.5% (29/40) |
| Intra-abdominal abscess | 78.4% (40/51) | 77.8% (35/45) |
| Complicated diverticulitis | 71.9% (23/32) | 71.4% (30/42) |
| Gastric and duodenal perforations | 92.0% (23/25) | 92.0% (23/25) |
| Peritonitis | 88.9% (16/18) | 90.0% (18/20) |
| Other | 66.7% (2/3) | 60.0% (3/5) |
TYGACIL is indicated for the treatment of adults with complicated intra-abdominal infections caused by the following pathogens1:
Key clinical cure rates in cIAI in microbiologically evaluable patients1
| Pathogen | TYGACIL monotherapy % (n/N) |
Imipenem/cilastatin % (n/N) |
|---|---|---|
| Gram negatives | ||
| Escherichia coli | 85.4% (281/329) | 86.9% (298/343) |
| Klebsiella pneumoniae | 88.5% (46/52) | 88.3% (53/60) |
| Klebsiella oxytoca | 95.0% (19/20) | 90.0% (18/20) |
| Enterobacter cloacae | 87.5% (14/16) | 94.1% (16/17) |
| Citrobacter freundii | 75.0% (12/16) | 75.0% (3/4) |
| Gram positives | ||
| Enterococcus faecalis (vancomycin-susceptible) |
75.8% (25/33) | 74.5% (35/47) |
| Streptococcus anginosus grp.* | 85.0% (102/120) | 75.3% (61/81) |
| Staphylococcus aureus (MSSA) | 89.7% (26/29) | 91.7% (22/24) |
| Anaerobes | ||
| Bacteroides fragilis | 77.0% (67/87) | 81.1% (60/74) |
| Bacteroides thetaiotaomicron | 87.8% (36/41) | 86.1% (31/36) |
| Clostridium perfringens | 95.0% (19/20) | 90.9% (20/22) |
| Bacteroides uniformis | 70.6% (12/17) | 82.4% (14/17) |
| Bacteroides vulgatus | 87.5% (14/16) | 71.4% (5/7) |
| Peptostreptococcus micros | 77.8% (14/18) | 75.0% (9/12) |
* Includes S. anginosus, S. intermedius, and S. constellatus.
Results from clinical studies demonstrated the efficacy of tigecycline in treating cIAI and its noninferiority to comparator therapy. View the cIAI studies.
Review case studies for examples of how TYGACIL provides effective, simplified management for cIAI.1
Indications and Important Safety Information
Indications
TYGACIL® (tigecycline) is indicated for the treatment of adults with:
- Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, and Bacteroides fragilis
- Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros
Important Safety Information
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria
- Anaphylaxis/anaphylactoid reactions have been reported with nearly all antibacterial agents, including tigecycline, and may be life-threatening
- TYGACIL is contraindicated in patients with known hypersensitivity to tigecycline
- TYGACIL should be administered with caution in patients with known hypersensitivity to tetracycline class antibiotics
- Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics and may have similar adverse effects. Such effects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis has been reported with the use of TYGACIL
- The safety and efficacy of TYGACIL in patients with hospital-acquired pneumonia have not been established
- In clinical trials, the most common treatment-emergent adverse events in patients treated with TYGACIL were nausea (29.5%) and vomiting (19.7%)
- TYGACIL may cause fetal harm when administered to a pregnant woman
- The safety and effectiveness of TYGACIL in patients below age 18 and lactating women have not been established
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range in severity from mild diarrhea to fatal colitis
- Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective
- The use of TYGACIL during tooth development may cause permanent discoloration of the teeth. TYGACIL should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated
- Prothrombin time or other suitable anticoagulant test should be monitored if TYGACIL is administered with warfarin
- Monotherapy should be used with caution in patients with clinically apparent intestinal perforation
- In patients with severe hepatic impairment (Child Pugh C), the initial dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours. Patients should be treated with caution and monitored for treatment response
- The following drugs should not be administered simultaneously through the same Y‑site as TYGACIL: amphotericin B and diazepam
Please see Prescribing Information
205930-01